{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:45Z","timestamp":1792791585272,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020648","name":"The Royal College of Physicians of Thailand","doi-asserted-by":"publisher","award":["02\/2564"],"award-info":[{"award-number":["02\/2564"]}],"id":[{"id":"10.13039\/100020648","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05b4yk834","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006439","name":"Mahidol University Faculty of Tropical Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006439","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lansea.2026.100862","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:46:53Z","timestamp":1789483613000},"page":"100862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5067-5389","authenticated-orcid":false,"given":"Rattagan","family":"Kajeekul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-9619","authenticated-orcid":false,"given":"Narisa","family":"Ruenroengbun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirichai","family":"Wiwatrojanagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannarin","family":"Kirdtongkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walinda","family":"Chantaranothai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairil Erwan","family":"Bin Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-5550","authenticated-orcid":false,"given":"Rujipas","family":"Sirijatuphat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1602-5435","authenticated-orcid":false,"given":"Thundon","family":"Ngamprasertchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lansea.2026.100862_bib1","series-title":"Policy brief: update of recommendations on first-and second-line antiretroviral regimens","year":"2019"},{"key":"10.1016\/j.lansea.2026.100862_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241260613","article-title":"A review of dolutegravir-associated weight gain and secondary metabolic comorbidities","volume":"12","author":"Jemal","year":"2024","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.lansea.2026.100862_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/QAI.0000000000003087","article-title":"Weight gain among treatment-naive persons with HIV receiving Dolutegravir in Kenya","volume":"91","author":"Bourgi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lansea.2026.100862_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2023.1133556","article-title":"Risks of metabolic syndrome in the ADVANCE and NAMSAL trials","volume":"5","author":"Tovar Sanchez","year":"2023","journal-title":"Front Reprod Health"},{"key":"10.1016\/j.lansea.2026.100862_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"16","key":"10.1016\/j.lansea.2026.100862_bib6","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.3390\/jcm10163456","article-title":"Do all integrase strand transfer inhibitors have the same lipid profile? Review of randomised controlled trials in na\u00efve and switch scenarios in HIV-infected patients","volume":"10","author":"Saumoy","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.lansea.2026.100862_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lansea.2026.100862_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lansea.2026.100862_bib9","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.18.1.20037","article-title":"Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy","volume":"18","author":"Gianotti","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.lansea.2026.100862_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.lansea.2026.100862_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1310\/hct1405-216","article-title":"Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine\/tenofovir disoproxil fumarate-based single-tablet regimens","volume":"14","author":"Mills","year":"2013","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.lansea.2026.100862_bib12","first-page":"1","article-title":"Kidney disease: improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"Suppl 1","key":"10.1016\/j.lansea.2026.100862_bib13","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lansea.2026.100862_bib14","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lansea.2026.100862_bib15","series-title":"Panel on antiretroviral guidelines for adults and adolescents, guidelines for the use of antiretroviral agents in adults and adolescents with HIV: appendix B\u2014Antiretroviral dosing recommendations in adults with renal or hepatic insufficiency","year":"2025"},{"key":"10.1016\/j.lansea.2026.100862_bib16","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV: virologic failure","year":"2024"},{"key":"10.1016\/j.lansea.2026.100862_bib17","series-title":"The role of HIV viral suppression in improving individual health and reducing transmission: policy brief","year":"2023"},{"key":"10.1016\/j.lansea.2026.100862_bib18","series-title":"De Novo Decision Summary: sentosa\u00ae SQ HIV-1 Genotyping Assay. De Novo Number BR190330","year":"2019"},{"key":"10.1016\/j.lansea.2026.100862_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.lansea.2026.100862_bib21","series-title":"Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment: guidance for industry, revision 1","year":"2015"},{"key":"10.1016\/j.lansea.2026.100862_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz297","article-title":"Switching Tenofovir\/Emtricitabine\/Efavirenz (TDF\/FTC\/EFV) to TDF\/FTC\/Rilpivirine vs continuing TDF\/FTC\/EFV in HIV-infected patients with virological suppression: a randomized controlled trial","volume":"6","author":"Wiriyatanakorn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lansea.2026.100862_bib23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lansea.2026.100862_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FPC.0000000000000515","article-title":"Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens","volume":"34","author":"Wu","year":"2024","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.lansea.2026.100862_bib25","doi-asserted-by":"crossref","first-page":"e2153","DOI":"10.1093\/cid\/ciaa1219","article-title":"Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens","volume":"73","author":"Leonard","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lansea.2026.100862_bib26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jcph.107","article-title":"Impact of food and different meal types on the pharmacokinetics of rilpivirine","volume":"53","author":"Crauwels","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.lansea.2026.100862_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.33393\/dti.2023.2529","article-title":"Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir","volume":"17","author":"Khemla","year":"2023","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.lansea.2026.100862_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-naive Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.lansea.2026.100862_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12879-018-3268-5","article-title":"Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)","volume":"18","author":"Taramasso","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lansea.2026.100862_bib30","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus","volume":"75","author":"O'Halloran","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lansea.2026.100862_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-003136","article-title":"Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis","volume":"11","author":"Mulindwa","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.lansea.2026.100862_bib32","first-page":"199","article-title":"Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"Gutierrez","year":"2014","journal-title":"AIDS Rev"},{"key":"10.1016\/j.lansea.2026.100862_bib33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.lansea.2026.100862_bib34","first-page":"6","article-title":"HIV drug resistance among pre-treatment cases in Thailand: four rounds of surveys during 2006-2013","volume":"11","author":"Thanprasertsuk","year":"2018","journal-title":"Outbreak Surveill Investig Rep"},{"key":"10.1016\/j.lansea.2026.100862_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dky443","article-title":"Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries","volume":"74","author":"Ngo-Giang-Huong","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lansea.2026.100862_bib36","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/QAI.0b013e31827a34b2","article-title":"Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia","volume":"62","author":"Sungkanuparph","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lansea.2026.100862_bib37","first-page":"152","article-title":"High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A\/E is predominant","volume":"5","author":"Chetchotisakd","year":"2006","journal-title":"J Int Assoc Phys AIDS Care"},{"issue":"4","key":"10.1016\/j.lansea.2026.100862_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154221","article-title":"Role of rilpivirine and etravirine in efavirenz and nevirapine-based regimens failure in a resource-limited country: a cross-sectional study","volume":"11","author":"Teeranaipong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lansea.2026.100862_bib39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/IDR.S196448","article-title":"Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam","volume":"12","author":"Tien","year":"2019","journal-title":"Infect Drug Resist"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368226001472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368226001472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:00:16Z","timestamp":1792789216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368226001472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S2772368226001472"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2026.100862","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2026.100862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100862"}}